Leerink Partnrs Has Positive Outlook for EW FY2025 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for shares of Edwards Lifesciences in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will earn $2.42 per share for the year, up from their prior forecast of $2.41. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2028 earnings at $3.71 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

Several other equities research analysts have also recently commented on EW. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Piper Sandler lifted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $78.55.

Edwards Lifesciences Stock Performance

Shares of EW opened at $71.56 on Friday. The firm’s 50 day moving average price is $71.31 and its two-hundred day moving average price is $70.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $95.25. The firm has a market cap of $42.07 billion, a P/E ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.15.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,853 shares of company stock valued at $5,163,062. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $610,895,000. Jennison Associates LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $555,939,000. Vanguard Group Inc. increased its stake in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Assenagon Asset Management S.A. raised its holdings in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $213,844,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.